Follicular Lymphoma - Pipeline Review, H2 2013

Follicular Lymphoma - Pipeline Review, H2 2013

Jul 2013 Global Markets Direct Lymphoma149 Pages Price :
$ 2000

Global Markets Directs, Follicular Lymphoma Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Follicular Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Follicular Lymphoma. Follicular Lymphoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Follicular Lymphoma.
  • A review of the Follicular Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Follicular Lymphoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Follicular Lymphoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Follicular Lymphoma 10
Follicular Lymphoma Therapeutics under Development by Companies 12
Follicular Lymphoma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Follicular Lymphoma Therapeutics Products under Development by Companies 19
Follicular Lymphoma Therapeutics Products under Investigation by Universities/Institutes 20
Companies Involved in Follicular Lymphoma Therapeutics Development 21
Bristol-Myers Squibb Company 21
F. Hoffmann-La Roche Ltd. 22
Biogen Idec Inc. 23
Sanofi-Aventis 24
Merck & Co., Inc. 25
Reliance Life Sciences Pvt. Ltd. 26
Celltrion, Inc. 27
Novartis AG 28
Genmab A/S 29
Sandoz Inc. 30
Celgene Corporation 31
Bayer AG 32
IMMUNOMEDICS, INC 33
MethylGene Inc 34
Accentia Biopharmaceuticals, Inc. 35
Pharmacyclics, Inc. 36
Cancer Research Technology Limited 37
Memgen, LLC. 38
AmpliMed Corporation 39
CureTech Ltd. 40
Follicular Lymphoma Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 47
obinutuzumab - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
mocetinostat - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ibrutinib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
abexinostat hydrochloride - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
SAR-245409 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
dasiprotimut T - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ISF-35 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
imexon - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BMS-936564 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
pidilizumab - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
epratuzumab - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
buparlisib - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
lenalidomide - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
DI-Leu16-IL2 Immunocytokine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ofatumumab - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
rituximab - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
ocaratuzumab - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
rituximab biosimilar - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
rituximab biosimilar - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
ABT-199 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
rituximab biosimilar - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
rituximab biosimilar - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
131I-Rituximab - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Andrographolide - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
interferon alfa-2b biosimilar - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
DNA Fusion Vaccines - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Follicular Lymphoma Therapeutics Drug Profile Updates 102
Follicular Lymphoma Therapeutics Discontinued Products 136
Follicular Lymphoma Therapeutics - Dormant Products 137
Follicular Lymphoma Product Development Milestones 138
Featured News & Press Releases 138
Jun 03, 2013: MethylGene Presents Clinical Data On Mocetinostat At ASCO 2013 Annual Meeting 138
May 28, 2013: MethylGene To Present Mocetinostat Data At 2013 ASCO Annual Meeting 138
May 15, 2013: Janssen Oncology Announces Presentation Of Data On Ibrutinib At 2013 ASCO Annual Meeting 139
Mar 07, 2013: Biovest Files Recapitalization Plan To Strengthen Balance Sheet And Advance Commercialization Strategy For BiovaxID Cancer Vaccine 140
Dec 11, 2012: Pharmacyclics Announces Updated Results For BTK Inhibitor Ibrutinib At American Society Of Hematology Annual Meeting 141
Dec 11, 2012: Celgene Presents Data Evaluating Combination Treatments Including Revlimid Plus Antibody Therapies In Patients With Various Forms Of Non-Hodgkin Lymphoma At ASH 2012 143
Dec 08, 2012: Roche Reports Positive Results From Two Studies Of MabThera Given By Subcutaneous Injection 144
Nov 09, 2012: ProNAi Presents Encouraging Phase I Study Results Of PNT2258 At Cancer Meeting 145
Nov 05, 2012: Genmab To Present Data On Ofatumumab At ASH Annual Meeting 146
Oct 09, 2012: Seattle Genetics Achieves Milestones As Genentech Advances Two Antibody-Drug Conjugates Into Phase II Development 146

Appendix 148
Methodology 148
Coverage 148
Secondary Research 148
Primary Research 148
Expert Panel Validation 148
Contact Us 149
Disclaimer 149

List of Table


Number of Products Under Development for Follicular Lymphoma, H2 2013 10
Products under Development for Follicular Lymphoma Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Clinical Stage Development, H2 2013 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 18
Products under Development by Companies, H2 2013 19
Products under Investigation by Universities/Institutes, H2 2013 20
Bristol-Myers Squibb Company, H2 2013 21
F. Hoffmann-La Roche Ltd., H2 2013 22
Biogen Idec Inc., H2 2013 23
Sanofi-Aventis, H2 2013 24
Merck & Co., Inc., H2 2013 25
Reliance Life Sciences Pvt. Ltd., H2 2013 26
Celltrion, Inc., H2 2013 27
Novartis AG, H2 2013 28
Genmab A/S, H2 2013 29
Sandoz Inc., H2 2013 30
Celgene Corporation, H2 2013 31
Bayer AG, H2 2013 32
IMMUNOMEDICS, INC, H2 2013 33
MethylGene Inc, H2 2013 34
Accentia Biopharmaceuticals, Inc., H2 2013 35
Pharmacyclics, Inc., H2 2013 36
Cancer Research Technology Limited, H2 2013 37
Memgen, LLC., H2 2013 38
AmpliMed Corporation, H2 2013 39
CureTech Ltd., H2 2013 40
Assessment by Monotherapy Products, H2 2013 41
Assessment by Stage and Route of Administration, H2 2013 43
Assessment by Stage and Molecule Type, H2 2013 46
Follicular Lymphoma Therapeutics Drug Profile Updates 102
Follicular Lymphoma Therapeutics Discontinued Products 136
Follicular Lymphoma Therapeutics Dormant Products 137

List of Chart


Number of Products under Development for Follicular Lymphoma, H2 2013 10
Products under Development for Follicular Lymphoma Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 14
Late Stage Products, H2 2013 15
Mid Clinical Stage Products, H2 2013 16
Early Clinical Stage Products, H2 2013 17
Discovery and Pre-Clinical Stage Products, H2 2013 18
Assessment by Monotherapy Products, H2 2013 41
Assessment by Route of Administration, H2 2013 42
Assessment by Stage and Route of Administration, H2 2013 43
Assessment by Molecule Type, H2 2013 44
Assessment by Stage and Molecule Type, H2 2013 45

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top